Otonomy, Inc. OTIC
We take great care to ensure that the data presented and summarized in this overview for OTONOMY, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in OTIC
Top Purchases
Top Sells
About OTIC
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase IIa clinical trials for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties. It also develops OTO-510, an otoprotectant for the prevention of cisplatin-induced hearing loss; OTO-825, a gene therapy for the treatment of congenital hearing loss; and OTO-6XX induces hair cell repair and regeneration for the treatment of severe hearing loss. The company has license agreements with University of California and DURECT Corporation; and strategic collaboration with Applied Genetic Technologies Corporation to develop and commercialize gene therapy for congenital hearing loss. Otonomy, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Insider Transactions at OTIC
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 30
2022
|
David Allen Weber Director |
SELL
Payment of exercise price or tax liability
|
Direct |
91,636
-24.27%
|
$0
$0.09 P/Share
|
|
Dec 28
2022
|
Paul E Cayer President and CFBO |
SELL
Payment of exercise price or tax liability
|
Direct |
40,054
-17.9%
|
$0
$0.09 P/Share
|
|
Nov 28
2022
|
Vickie L Capps Director |
SELL
Open market or private sale
|
Direct |
42,242
-92.55%
|
$0
$0.1 P/Share
|
|
Mar 28
2022
|
Paul E Cayer President and CFBO |
SELL
Open market or private sale
|
Direct |
5,624
-2.45%
|
$11,248
$2.41 P/Share
|
|
Mar 28
2022
|
Alan Charles Foster Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,559
-1.43%
|
$5,118
$2.41 P/Share
|
|
Mar 28
2022
|
Robert Michael Savel Ii Chief Technical Officer |
SELL
Open market or private sale
|
Direct |
3,325
-2.23%
|
$6,650
$2.41 P/Share
|
|
Mar 28
2022
|
David Allen Weber Director |
SELL
Open market or private sale
|
Direct |
11,243
-2.89%
|
$22,486
$2.41 P/Share
|
|
Mar 25
2022
|
Paul E Cayer President and CFBO |
SELL
Open market or private sale
|
Direct |
4,015
-1.72%
|
$8,030
$2.39 P/Share
|
|
Mar 25
2022
|
Alan Charles Foster Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,827
-1.01%
|
$3,654
$2.39 P/Share
|
|
Mar 25
2022
|
Robert Michael Savel Ii Chief Technical Officer |
SELL
Open market or private sale
|
Direct |
2,374
-1.57%
|
$4,748
$2.39 P/Share
|
|
Mar 25
2022
|
David Allen Weber Director |
SELL
Open market or private sale
|
Direct |
8,026
-2.02%
|
$16,052
$2.39 P/Share
|
|
Jan 14
2022
|
David Allen Weber Director |
BUY
Grant, award, or other acquisition
|
Direct |
150,000
+27.43%
|
-
|
|
Jan 14
2022
|
Robert Michael Savel Ii Chief Technical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
70,000
+31.61%
|
-
|
|
Jan 14
2022
|
Alan Charles Foster Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
70,000
+27.84%
|
-
|
|
Jan 14
2022
|
Paul E Cayer President and CFBO |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+29.99%
|
-
|
|
Apr 16
2021
|
David Allen Weber Director |
BUY
Grant, award, or other acquisition
|
Direct |
220,000
+47.13%
|
-
|
|
Apr 16
2021
|
Paul E Cayer President and CFBO |
BUY
Grant, award, or other acquisition
|
Direct |
110,000
+45.19%
|
-
|
|
Apr 16
2021
|
Robert Michael Savel Ii Chief Technical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
65,000
+44.39%
|
-
|
|
Mar 03
2021
|
Jay Lichter Director |
SELL
Open market or private sale
|
Indirect |
321,180
-100.0%
|
$642,360
$2.7 P/Share
|
|
Mar 02
2021
|
Jay Lichter Director |
SELL
Open market or private sale
|
Indirect |
389,574
-54.81%
|
$779,148
$2.9 P/Share
|